158 related articles for article (PubMed ID: 31830634)
1. Synthesis and structure-activity relationship studies of α-naphthoflavone derivatives as CYP1B1 inhibitors.
Dong J; Wang Z; Cui J; Meng Q; Li S
Eur J Med Chem; 2020 Feb; 187():111938. PubMed ID: 31830634
[TBL] [Abstract][Full Text] [Related]
2. Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors.
Dong J; Huang G; Cui Q; Meng Q; Li S; Cui J
Eur J Med Chem; 2021 Jan; 209():112895. PubMed ID: 33069055
[TBL] [Abstract][Full Text] [Related]
3. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression.
Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S
J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264
[TBL] [Abstract][Full Text] [Related]
4. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship.
Chen P; Wang S; Cao C; Ye W; Wang M; Zhou C; Chen W; Zhang X; Zhang K; Zhou W
Bioorg Chem; 2021 Nov; 116():105295. PubMed ID: 34455300
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of selective CYP1B1 inhibitor via dearomatization of α-naphthoflavone.
Kubo M; Yamamoto K; Itoh T
Bioorg Med Chem; 2019 Jan; 27(2):285-304. PubMed ID: 30553624
[TBL] [Abstract][Full Text] [Related]
6. Perspective of structural flexibility on selective inhibition towards CYP1B1 over CYP1A1 by α-naphthoflavone analogs.
Wang Y; Hu B; Zhang Y; Wang D; Luo Z; Wang J; Zhang F
Phys Chem Chem Phys; 2021 Sep; 23(36):20230-20246. PubMed ID: 34474468
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation.
Zhou L; Chen W; Cao C; Shi Y; Ye W; Hu J; Wang L; Zhou W
Eur J Med Chem; 2020 Mar; 189():112028. PubMed ID: 31945665
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human CYP1 enzymes by a classical inhibitor α-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study.
Juvonen RO; Jokinen EM; Javaid A; Lehtonen M; Raunio H; Pentikäinen OT
Chem Biol Drug Des; 2020 May; 95(5):520-533. PubMed ID: 32060993
[TBL] [Abstract][Full Text] [Related]
9. Identification of CYP1B1-specific candidate inhibitors using combination of in silico screening, integrated knowledge-based filtering, and molecular dynamics simulations.
Kumar R; Gupta D
Chem Biol Drug Des; 2016 Nov; 88(5):730-739. PubMed ID: 27300691
[TBL] [Abstract][Full Text] [Related]
10. A new class of CYP1B1 inhibitors derived from bentranil.
Yi L; Huang X; Yang M; Cai J; Jia J; Peng Z; Zhao Z; Yang F; Qiu D
Bioorg Med Chem Lett; 2023 Jan; 80():129112. PubMed ID: 36565966
[TBL] [Abstract][Full Text] [Related]
11. Targeting Cytochrome P450 (CYP) 1B1 Enzyme with Four Series of A-Ring Substituted Estrane Derivatives: Design, Synthesis, Inhibitory Activity, and Selectivity.
Dutour R; Roy J; Cortés-Benítez F; Maltais R; Poirier D
J Med Chem; 2018 Oct; 61(20):9229-9245. PubMed ID: 30216063
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1.
Mikstacka R; Rimando AM; Dutkiewicz Z; Stefański T; Sobiak S
Bioorg Med Chem; 2012 Sep; 20(17):5117-26. PubMed ID: 22863525
[TBL] [Abstract][Full Text] [Related]
13. Biphenyl urea derivatives as selective CYP1B1 inhibitors.
Mohd Siddique MU; McCann GJ; Sonawane V; Horley N; Williams IS; Joshi P; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
Org Biomol Chem; 2016 Sep; 14(38):8931-8936. PubMed ID: 27714268
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification.
Wang Y; He X; Li C; Ma Y; Xue W; Hu B; Wang J; Zhang T; Zhang F
Eur J Med Chem; 2020 May; 193():112235. PubMed ID: 32203789
[TBL] [Abstract][Full Text] [Related]
15. Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme.
Sharma R; Gatchie L; Williams IS; Jain SK; Vishwakarma RA; Chaudhuri B; Bharate SB
Bioorg Med Chem Lett; 2017 Dec; 27(24):5400-5403. PubMed ID: 29150398
[TBL] [Abstract][Full Text] [Related]
16. Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
Lee D; Perez P; Jackson W; Chin T; Galbreath M; Fronczek FR; Isovitsch R; Iimoto DS
Bioorg Med Chem Lett; 2016 Jul; 26(14):3243-3247. PubMed ID: 27265259
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, biological evaluation and docking studies of trans-stilbene methylthio derivatives as cytochromes P450 family 1 inhibitors.
Wierzchowski M; Dutkiewicz Z; Gielara-Korzańska A; Korzański A; Teubert A; Teżyk A; Stefański T; Baer-Dubowska W; Mikstacka R
Chem Biol Drug Des; 2017 Dec; 90(6):1226-1236. PubMed ID: 28632937
[TBL] [Abstract][Full Text] [Related]
18. Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives.
Poirier D; Roy J; Cortés-Benítez F; Dutour R
Bioorg Med Chem Lett; 2016 Nov; 26(21):5272-5276. PubMed ID: 27687674
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis and Binding Affinity Evaluation of Cytochrome P450 1B1 Targeted Chelators.
Chen D; Fan Q; Xu T; Dong J; Cui J; Wang Z; Wang J; Meng Q; Li S
Anticancer Agents Med Chem; 2022; 22(2):261-269. PubMed ID: 33820523
[TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.
Horley NJ; Beresford KJ; Chawla T; McCann GJ; Ruparelia KC; Gatchie L; Sonawane VR; Williams IS; Tan HL; Joshi P; Bharate SS; Kumar V; Bharate SB; Chaudhuri B
Eur J Med Chem; 2017 Mar; 129():159-174. PubMed ID: 28222316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]